Email Template

Email Your School

Inform your child’s healthcare team on how to handle low blood sugar and ensure they’re ready to help

Fill in the blanks below

We'll automatically generate an email for you to share with your child's caregiver.

Email preview

Dear {{caregiversNameFilter}},

I hope this email finds you well. I wanted to take a moment to share some important information about my child, {{childsNameFilter}}. {{childsNameFilter}} has diabetes, so it's important to keep a close eye on their blood sugar levels throughout the day and to be prepared to step in if needed.

A serious complication of diabetes is low blood sugar which can be life-threatening if left untreated. Low blood sugar occurs when blood sugar levels drop below 70 mg/dL. Signs and symptoms may include shakiness, dizziness, confusion, combative behavior, fatigue, and difficulty speaking. My child's symptoms are: {{symptomsFilter}}.

Here is what to do for low blood sugar:

1. Address it immediately.

If {{childsNameFilter}} is below 70 mg/dL (mild) or below 54 mg/dL (moderate), it is recommended to treat promptly with 15 grams of oral fast-acting carbohydrates (e.g., glucose tablets, fruit snacks, juice). Then, retest in 15 minutes and repeat the process until their target blood sugar level is reached.

In these cases, low blood sugar snacks or glucose tablets for {{childsNameFilter}} can be found in {{locationSnacksFilter}}.

2. Recognize when something more is needed.

There are times when eating or drinking isn't enough to correct low blood sugar and it becomes an emergency. For example, if {{childsNameFilter}} is:

Unable or unwilling to eat or drink
Feels like passing out
Passes out or has a seizure

In emergencies like those stated above, they have a ready-to-use rescue pen called Gvoke HypoPen^® to treat very low blood sugar. It can be found in {{locationGvokeFilter}}. I ask that you please watch this instructional video to learn how to use it: https://bit.ly/3TAIsv9. After using Gvoke HypoPen, make sure to turn them on their side if they are passed out and call for emergency help.

If there are any questions or if you need further clarification on helping {{childsNameFilter}}, please feel free to contact me. Thank you sincerely for your attention to this matter and your support.

Best Regards,
{{gardiansNameFilter}}

Indication and Important Safety Information⁠—⁠Read More

INDICATION AND IMPORTANT SAFETY INFORMATION

GVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications

GVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in GVOKE. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions

GVOKE is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GVOKE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GVOKE, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon. These include generalized rash, and in some cases, anaphylactic shock with breathing difficulties and hypotension. GVOKE is contraindicated in patients with a prior hypersensitivity reaction.
GVOKE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia, may not have adequate levels of hepatic glycogen for GVOKE administration to be effective. Patients with these conditions should be treated with glucose.

Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.

Adverse Reactions

Most common (≥5%) adverse reactions associated with GVOKE are nausea, vomiting, injection site edema (raised 1 mm or greater), and hypoglycemia.

Drug Interactions

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE. In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. GVOKE may increase the anticoagulant effect of warfarin.

Please see the Full Prescribing Information for Gvoke.

Gvoke®, Gvoke HypoPen®, Xeris Pharmaceuticals®, and their associated logos are trademarks of Xeris Pharmaceuticals, Inc. All other trademarks are property of their respective owners.

Privacy Shield Policy

Financial Conflict of Interest

Sitemap